There were 22 press releases posted in the last 24 hours and 166,034 in the last 365 days.

Global HIV Drugs Industry

HIV Drugs market worldwide is projected to grow by US$6. 3 Billion, driven by a compounded growth of 3. 6%. Multi-Class Combination Drugs, one of the segments analyzed and sized in this study, displays the potential to grow at over 4%.

/EIN News/ -- New York, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global HIV Drugs Industry" - https://www.reportlinker.com/p05817960/?utm_source=GNW
The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$10.4 Billion by the year 2025, Multi-Class Combination Drugs will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 2.8% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$229.7 Million to the region’s size and clout in the next 5 to 6 years. Over US$185.9 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Multi-Class Combination Drugs will reach a market size of US$549.9 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 5.7% over the next couple of years and add approximately US$1.8 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include among others, AbbVie, Inc.; AstraZeneca PLC; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Cipla Ltd.; Daiichi Sankyo Co., Ltd.; Emcure Pharmaceuticals Pvt., Ltd.; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Hetero Drugs Ltd.; Johnson & Johnson; Merck & Co., Inc.; Teva Pharmaceutical Industries Ltd.; ViiV Healthcare


Read the full report: https://www.reportlinker.com/p05817960/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
HIV Drugs Competitor Market Share Scenario Worldwide (in %):
2019 & 2028
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: HIV Drugs Global Market Estimates and Forecasts in US$
Million by Region/Country: 2018-2025
Table 2: HIV Drugs Global Retrospective Market Scenario in US$
Million by Region/Country: 2009-2017
Table 3: HIV Drugs Market Share Shift across Key Geographies
Worldwide: 2009 VS 2019 VS 2025
Table 4: Multi-Class Combination Drugs (Medication Class) World
Market by Region/Country in US$ Million: 2018 to 2025
Table 5: Multi-Class Combination Drugs (Medication Class)
Historic Market Analysis by Region/Country in US$ Million: 2009
to 2017
Table 6: Multi-Class Combination Drugs (Medication Class)
Market Share Breakdown of Worldwide Sales by Region/Country:
2009 VS 2019 VS 2025
Table 7: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
(Medication Class) Potential Growth Markets Worldwide in US$
Million: 2018 to 2025
Table 8: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
(Medication Class) Historic Market Perspective by
Region/Country in US$ Million: 2009 to 2017
Table 9: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
(Medication Class) Market Sales Breakdown by Region/Country in
Percentage: 2009 VS 2019 VS 2025
Table 10: Non-Nucleoside Reverse Transcriptase Inhibitors
(NNRTIs) (Medication Class) Geographic Market Spread Worldwide
in US$ Million: 2018 to 2025
Table 11: Non-Nucleoside Reverse Transcriptase Inhibitors
(NNRTIs) (Medication Class) Region Wise Breakdown of Global
Historic Demand in US$ Million: 2009 to 2017
Table 12: Non-Nucleoside Reverse Transcriptase Inhibitors
(NNRTIs) (Medication Class) Market Share Distribution in
Percentage by Region/Country: 2009 VS 2019 VS 2025
Table 13: Protease Inhibitors (PIs) (Medication Class) World
Market Estimates and Forecasts by Region/Country in US$
Million: 2018 to 2025
Table 14: Protease Inhibitors (PIs) (Medication Class) Market
Historic Review by Region/Country in US$ Million: 2009 to 2017
Table 15: Protease Inhibitors (PIs) (Medication Class) Market
Share Breakdown by Region/Country: 2009 VS 2019 VS 2025
Table 16: Fusion Inhibitors (FI) (Medication Class) World
Market by Region/Country in US$ Million: 2018 to 2025
Table 17: Fusion Inhibitors (FI) (Medication Class) Historic
Market Analysis by Region/Country in US$ Million: 2009 to 2017
Table 18: Fusion Inhibitors (FI) (Medication Class) Market
Share Distribution in Percentage by Region/Country: 2009 VS
2019 VS 2025
Table 19: Entry Inhibitors (Medication Class) World Market
Estimates and Forecasts in US$ Million by Region/Country: 2018
to 2025
Table 20: Entry Inhibitors (Medication Class) Market Worldwide
Historic Review by Region/Country in US$ Million: 2009 to 2017
Table 21: Entry Inhibitors (Medication Class) Market Percentage
Share Distribution by Region/Country: 2009 VS 2019 VS 2025
Table 22: HIV Integrase Stand Transfer Inhibitors (Medication
Class) Market Opportunity Analysis Worldwide in US$ Million by
Region/Country: 2018 to 2025
Table 23: HIV Integrase Stand Transfer Inhibitors (Medication
Class) Global Historic Demand in US$ Million by Region/Country:
2009 to 2017
Table 24: HIV Integrase Stand Transfer Inhibitors (Medication
Class) Market Share Distribution in Percentage by
Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
US HIV Drugs Market Share (in %) by Company: 2019 & 2025
Table 25: United States HIV Drugs Market Estimates and
Projections in US$ Million by Medication Class: 2018 to 2025
Table 26: HIV Drugs Market in the United States by Medication
Class: A Historic Review in US$ Million for 2009-2017
Table 27: United States HIV Drugs Market Share Breakdown by
Medication Class: 2009 VS 2019 VS 2025
CANADA
Table 28: Canadian HIV Drugs Market Estimates and Forecasts in
US$ Million by Medication Class: 2018 to 2025
Table 29: Canadian HIV Drugs Historic Market Review by
Medication Class in US$ Million: 2009-2017
Table 30: HIV Drugs Market in Canada: Percentage Share
Breakdown of Sales by Medication Class for 2009, 2019, and 2025
JAPAN
Table 31: Japanese Market for HIV Drugs: Annual Sales Estimates
and Projections in US$ Million by Medication Class for the
Period 2018-2025
Table 32: HIV Drugs Market in Japan: Historic Sales Analysis in
US$ Million by Medication Class for the Period 2009-2017
Table 33: Japanese HIV Drugs Market Share Analysis by
Medication Class: 2009 VS 2019 VS 2025
CHINA
Table 34: Chinese HIV Drugs Market Growth Prospects in US$
Million by Medication Class for the Period 2018-2025
Table 35: HIV Drugs Historic Market Analysis in China in US$
Million by Medication Class: 2009-2017
Table 36: Chinese HIV Drugs Market by Medication Class:
Percentage Breakdown of Sales for 2009, 2019, and 2025
EUROPE
Market Facts & Figures
European HIV Drugs Market: Competitor Market Share Scenario
(in %) for 2019 & 2025
Table 37: European HIV Drugs Market Demand Scenario in US$
Million by Region/Country: 2018-2025
Table 38: HIV Drugs Market in Europe: A Historic Market
Perspective in US$ Million by Region/Country for the Period
2009-2017
Table 39: European HIV Drugs Market Share Shift by
Region/Country: 2009 VS 2019 VS 2025
Table 40: European HIV Drugs Market Estimates and Forecasts in
US$ Million by Medication Class: 2018-2025
Table 41: HIV Drugs Market in Europe in US$ Million by
Medication Class: A Historic Review for the Period 2009-2017
Table 42: European HIV Drugs Market Share Breakdown by
Medication Class: 2009 VS 2019 VS 2025
FRANCE
Table 43: HIV Drugs Market in France by Medication Class:
Estimates and Projections in US$ Million for the Period
2018-2025
Table 44: French HIV Drugs Historic Market Scenario in US$
Million by Medication Class: 2009-2017
Table 45: French HIV Drugs Market Share Analysis by Medication
Class: 2009 VS 2019 VS 2025
GERMANY
Table 46: HIV Drugs Market in Germany: Recent Past, Current and
Future Analysis in US$ Million by Medication Class for the
Period 2018-2025
Table 47: German HIV Drugs Historic Market Analysis in US$
Million by Medication Class: 2009-2017
Table 48: German HIV Drugs Market Share Breakdown by Medication
Class: 2009 VS 2019 VS 2025
ITALY
Table 49: Italian HIV Drugs Market Growth Prospects in US$
Million by Medication Class for the Period 2018-2025
Table 50: HIV Drugs Historic Market Analysis in Italy in US$
Million by Medication Class: 2009-2017
Table 51: Italian HIV Drugs Market by Medication Class:
Percentage Breakdown of Sales for 2009, 2019, and 2025
UNITED KINGDOM
Table 52: United Kingdom Market for HIV Drugs: Annual Sales
Estimates and Projections in US$ Million by Medication Class
for the Period 2018-2025
Table 53: HIV Drugs Market in the United Kingdom: Historic
Sales Analysis in US$ Million by Medication Class for the
Period 2009-2017
Table 54: United Kingdom HIV Drugs Market Share Analysis by
Medication Class: 2009 VS 2019 VS 2025
SPAIN
Table 55: Spanish HIV Drugs Market Estimates and Forecasts in
US$ Million by Medication Class: 2018 to 2025
Table 56: Spanish HIV Drugs Historic Market Review by
Medication Class in US$ Million: 2009-2017
Table 57: HIV Drugs Market in Spain: Percentage Share Breakdown
of Sales by Medication Class for 2009, 2019, and 2025
RUSSIA
Table 58: Russian HIV Drugs Market Estimates and Projections in
US$ Million by Medication Class: 2018 to 2025
Table 59: HIV Drugs Market in Russia by Medication Class: A
Historic Review in US$ Million for 2009-2017
Table 60: Russian HIV Drugs Market Share Breakdown by
Medication Class: 2009 VS 2019 VS 2025
REST OF EUROPE
Table 61: Rest of Europe HIV Drugs Market Estimates and
Forecasts in US$ Million by Medication Class: 2018-2025
Table 62: HIV Drugs Market in Rest of Europe in US$ Million by
Medication Class: A Historic Review for the Period 2009-2017
Table 63: Rest of Europe HIV Drugs Market Share Breakdown by
Medication Class: 2009 VS 2019 VS 2025
ASIA-PACIFIC
Table 64: Asia-Pacific HIV Drugs Market Estimates and Forecasts
in US$ Million by Region/Country: 2018-2025
Table 65: HIV Drugs Market in Asia-Pacific: Historic Market
Analysis in US$ Million by Region/Country for the Period
2009-2017
Table 66: Asia-Pacific HIV Drugs Market Share Analysis by
Region/Country: 2009 VS 2019 VS 2025
Table 67: HIV Drugs Market in Asia-Pacific by Medication Class:
Estimates and Projections in US$ Million for the Period
2018-2025
Table 68: Asia-Pacific HIV Drugs Historic Market Scenario in
US$ Million by Medication Class: 2009-2017
Table 69: Asia-Pacific HIV Drugs Market Share Analysis by
Medication Class: 2009 VS 2019 VS 2025
AUSTRALIA
Table 70: HIV Drugs Market in Australia: Recent Past, Current
and Future Analysis in US$ Million by Medication Class for the
Period 2018-2025
Table 71: Australian HIV Drugs Historic Market Analysis in US$
Million by Medication Class: 2009-2017
Table 72: Australian HIV Drugs Market Share Breakdown by
Medication Class: 2009 VS 2019 VS 2025
INDIA
Table 73: Indian HIV Drugs Market Estimates and Forecasts in
US$ Million by Medication Class: 2018 to 2025
Table 74: Indian HIV Drugs Historic Market Review by Medication
Class in US$ Million: 2009-2017
Table 75: HIV Drugs Market in India: Percentage Share Breakdown
of Sales by Medication Class for 2009, 2019, and 2025
SOUTH KOREA
Table 76: HIV Drugs Market in South Korea: Recent Past, Current
and Future Analysis in US$ Million by Medication Class for the
Period 2018-2025
Table 77: South Korean HIV Drugs Historic Market Analysis in
US$ Million by Medication Class: 2009-2017
Table 78: HIV Drugs Market Share Distribution in South Korea by
Medication Class: 2009 VS 2019 VS 2025
REST OF ASIA-PACIFIC
Table 79: Rest of Asia-Pacific Market for HIV Drugs: Annual
Sales Estimates and Projections in US$ Million by Medication
Class for the Period 2018-2025
Table 80: HIV Drugs Market in Rest of Asia-Pacific: Historic
Sales Analysis in US$ Million by Medication Class for the
Period 2009-2017
Table 81: Rest of Asia-Pacific HIV Drugs Market Share Analysis
by Medication Class: 2009 VS 2019 VS 2025
LATIN AMERICA
Table 82: Latin American HIV Drugs Market Trends by
Region/Country in US$ Million: 2018-2025
Table 83: HIV Drugs Market in Latin America in US$ Million by
Region/Country: A Historic Perspective for the Period 2009-2017
Table 84: Latin American HIV Drugs Market Percentage Breakdown
of Sales by Region/Country: 2009, 2019, and 2025
Table 85: Latin American HIV Drugs Market Growth Prospects in
US$ Million by Medication Class for the Period 2018-2025
Table 86: HIV Drugs Historic Market Analysis in Latin America
in US$ Million by Medication Class: 2009-2017
Table 87: Latin American HIV Drugs Market by Medication Class:
Percentage Breakdown of Sales for 2009, 2019, and 2025
ARGENTINA
Table 88: Argentinean HIV Drugs Market Estimates and Forecasts
in US$ Million by Medication Class: 2018-2025
Table 89: HIV Drugs Market in Argentina in US$ Million by
Medication Class: A Historic Review for the Period 2009-2017
Table 90: Argentinean HIV Drugs Market Share Breakdown by
Medication Class: 2009 VS 2019 VS 2025
BRAZIL
Table 91: HIV Drugs Market in Brazil by Medication Class:
Estimates and Projections in US$ Million for the Period
2018-2025
Table 92: Brazilian HIV Drugs Historic Market Scenario in US$
Million by Medication Class: 2009-2017
Table 93: Brazilian HIV Drugs Market Share Analysis by
Medication Class: 2009 VS 2019 VS 2025
MEXICO
Table 94: HIV Drugs Market in Mexico: Recent Past, Current and
Future Analysis in US$ Million by Medication Class for the
Period 2018-2025
Table 95: Mexican HIV Drugs Historic Market Analysis in US$
Million by Medication Class: 2009-2017
Table 96: Mexican HIV Drugs Market Share Breakdown by
Medication Class: 2009 VS 2019 VS 2025
REST OF LATIN AMERICA
Table 97: Rest of Latin America HIV Drugs Market Estimates and
Projections in US$ Million by Medication Class: 2018 to 2025
Table 98: HIV Drugs Market in Rest of Latin America by
Medication Class: A Historic Review in US$ Million for
2009-2017
Table 99: Rest of Latin America HIV Drugs Market Share
Breakdown by Medication Class: 2009 VS 2019 VS 2025
MIDDLE EAST
Table 100: The Middle East HIV Drugs Market Estimates and
Forecasts in US$ Million by Region/Country: 2018-2025
Table 101: HIV Drugs Market in the Middle East by
Region/Country in US$ Million: 2009-2017
Table 102: The Middle East HIV Drugs Market Share Breakdown by
Region/Country: 2009, 2019, and 2025
Table 103: The Middle East HIV Drugs Market Estimates and
Forecasts in US$ Million by Medication Class: 2018 to 2025
Table 104: The Middle East HIV Drugs Historic Market by
Medication Class in US$ Million: 2009-2017
Table 105: HIV Drugs Market in the Middle East: Percentage
Share Breakdown of Sales by Medication Class for 2009, 2019,
and 2025
IRAN
Table 106: Iranian Market for HIV Drugs: Annual Sales Estimates
and Projections in US$ Million by Medication Class for the
Period 2018-2025
Table 107: HIV Drugs Market in Iran: Historic Sales Analysis in
US$ Million by Medication Class for the Period 2009-2017
Table 108: Iranian HIV Drugs Market Share Analysis by
Medication Class: 2009 VS 2019 VS 2025
ISRAEL
Table 109: Israeli HIV Drugs Market Estimates and Forecasts in
US$ Million by Medication Class: 2018-2025
Table 110: HIV Drugs Market in Israel in US$ Million by
Medication Class: A Historic Review for the Period 2009-2017
Table 111: Israeli HIV Drugs Market Share Breakdown by
Medication Class: 2009 VS 2019 VS 2025
SAUDI ARABIA
Table 112: Saudi Arabian HIV Drugs Market Growth Prospects in
US$ Million by Medication Class for the Period 2018-2025
Table 113: HIV Drugs Historic Market Analysis in Saudi Arabia
in US$ Million by Medication Class: 2009-2017
Table 114: Saudi Arabian HIV Drugs Market by Medication Class:
Percentage Breakdown of Sales for 2009, 2019, and 2025
UNITED ARAB EMIRATES
Table 115: HIV Drugs Market in the United Arab Emirates: Recent
Past, Current and Future Analysis in US$ Million by Medication
Class for the Period 2018-2025
Table 116: United Arab Emirates HIV Drugs Historic Market
Analysis in US$ Million by Medication Class: 2009-2017
Table 117: HIV Drugs Market Share Distribution in United Arab
Emirates by Medication Class: 2009 VS 2019 VS 2025
REST OF MIDDLE EAST
Table 118: HIV Drugs Market in Rest of Middle East: Recent
Past, Current and Future Analysis in US$ Million by Medication
Class for the Period 2018-2025
Table 119: Rest of Middle East HIV Drugs Historic Market
Analysis in US$ Million by Medication Class: 2009-2017
Table 120: Rest of Middle East HIV Drugs Market Share Breakdown
by Medication Class: 2009 VS 2019 VS 2025
AFRICA
Table 121: African HIV Drugs Market Estimates and Projections
in US$ Million by Medication Class: 2018 to 2025
Table 122: HIV Drugs Market in Africa by Medication Class: A
Historic Review in US$ Million for 2009-2017
Table 123: African HIV Drugs Market Share Breakdown by
Medication Class: 2009 VS 2019 VS 2025

IV. COMPETITION

ABBVIE
ASTRAZENECA PLC
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB COMPANY
CIPLA
DAIICHI SANKYO
EMCURE PHARMACEUTICALS PRIVATE LIMITED
F. HOFFMANN-LA ROCHE AG
GILEAD SCIENCES
JOHNSON & JOHNSON
MERCK & CO., INC.
TEVA PHARMACEUTICAL INDUSTRIES
VIIV HEALTHCARE

V. CURATED RESEARCH
Read the full report: https://www.reportlinker.com/p05817960/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
Distribution channels: Media, Advertising & PR


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.